Bristol-myers Company

Sankyo Company, Limited

Keiko Shimizu

Masataka Konishi

Toshikazu Oki

Koji Tomita

Takeo Miyaki

Tatsuo Haneishi

Takeshi Kinoshita

Masatoshi Inukai

Masaru Ohbayashi

Yoshiharu Sakaida

Fujio Isono

The process for producing mureidomycin A, B, C or D or a salt thereof by cultivating Streptomyces flavidovirens SANK 60486, FERM BP-1347, in a culture medium therefor and isolating mureidomycin A, B, C or D or a salt thereof from the cultured broth.

Fermentation process for preparing antibiotics mureidomycins A, B, C and

New antibiotics of the mureidomycin group have the formula ##STR1## wherein X represents the group ##STR2## and wherein R represents hydrogen, an alkyl group having from 1 to 10 carbon atoms, an alkenyl group having from 2 to 7 carbon atoms, an alkynyl group having from 3 to 7 carbon atoms, an aryl group having from 6 to 10 carbon atoms, an aralkyl group having from 7 to 10 carbon atoms, or one of the said aryl or aralkyl groups substituted with at least one substituent selected from halogen and alkyl groups having from 1 to 5 carbon atoms. The compound in which X represents 8-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl is named mureidomycin E and the compound in which X represents 6-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl is named mureidomycin F. This group of compounds and their pharmaceutically acceptable esters and salts are useful as antibiotics for the treatment of bacterial infections. Mureidomycins E and F can be obtained by fermentation of a suitable Streptomyces strain, in particular Streptomyces flaviodovirens SANK 60486 (BIKOKEN JOHKI 1347; FERM BP-1347). Alternatively, all of the compounds can be obtained synthetically by reacting the previously known compound mureidomycin A with an aldehyde of the formula

Antibiotics of the mureidomycin group, their preparation, and their

Novel compounds, called mureidomycins A, B, C and D, may be prepared by cultivation of a suitable microorganism of the genus Streptomyces, especially Streptomyces flavidovirens SANK 60486 (FERM P-8636, FERM BP-1347). These represent a wholly new class of antibiotics, which are valuable in the treatment of infections caused by a variety of bacteria, notably of the genus Pseudomonas.

Antibiotics called 'mureidomycins A, B, C, and D' and their therapeutic

A new antibiotic having the chromophore structure of the plurmycin family of antibiotics is produced by fermentation of Streptomyces violaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.

BU-3839T antibiotic

An new antibiotic having the chromophore structure of the pluramycin family of antibiotics is produced by fermentation of Streptomyces violaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.

Biological pure culture of Streptomyces violaceus ATCC 53807

A new antibiotic having the chromophore structure of the pluramycin family of antibiotics is produced by fermentation of Streptomyces ciolaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.

Growing community of inventors

Tokyo, Japan

Keiko Shimizu